C9ORF72 poly-PR disrupts expression of ALS/FTD-implicated STMN2 through SRSF7
A hexanucleotide repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and combined ALS/FTD. The repeat is transcribed in the sense and the antisense directions to produce several dipeptide repeat proteins (DPRs) that have toxic gain-of-function effects; however, the mechanisms by which DPRs lead to neural dysfunction remain unresolved. Here, we observed that poly-proline-arginine (poly-PR) was sufficient to inhibit axonal regeneration of human induced pluripotent stem cell (iPSC)-derived neurons. Global phospho-proteomics revealed that poly-PR selectively perturbs nuclear RNA binding proteins (RBPs). In neurons, we found that depletion of one of these RBPs, SRSF7 (serine/arginine-rich splicing factor 7), resulted in decreased abundance of STMN2 (stathmin-2), though not TDP-43. STMN2 supports axon maintenance and repair and has been recently implicated in the pathogenesis of ALS/FTD. We observed that depletion of SRSF7 impaired axonal regeneration, a phenotype that could be rescued by exogenous STMN2. We propose that antisense repeat-encoded poly-PR perturbs RBPs, particularly SRSF7, resulting in reduced STMN2 and axonal repair defects in neurons. Hence, we provide a potential link between DPRs gain-of-function effects and STMN2 loss-of-function phenotypes in neurodegeneration.
Authors
- Bogdan Budnik (ORCID: https://orcid.org/0000-0003-3622-2003)
- Karen S. Wang
- Julie Smeyers (ORCID: https://orcid.org/0000-0001-5661-1546)
- Kevin Eggan (ORCID: https://orcid.org/0000-0003-4436-8467)
- Daniel A. Mordes
Institutions
- Broad Institute (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Massachusetts General Hospital (US)
- Institute for Neurodegenerative Disorders (US)
Publication Details
- Journal
- Acta Neuropathologica Communications
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1186/s40478-025-01977-2
- Citations
- 4
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- Target ALS
- National Institutes of Health
- Harvard Stem Cell Institute
- University of California, San Francisco
- National Institute of Neurological Disorders and Stroke
- Congressionally Directed Medical Research Programs